ArticleObesity (Silver Spring, Md.)2023
Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: A retrospective cohort study.
Article in Obesity (Silver Spring, Md.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.Medicine · 2026 · on this mapPooled it
- Methylphenidate can help reduce weight, appetite, and food intake-a narrative review of adults' anthropometric changes and feeding behaviors.Frontiers in nutrition · 2024Pooled it
- Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia · 2026Article
- Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity.Scientific reports · 2026Article
- Roux-en-Y gastric bypass results in long-term durable weight loss and diabetes remission: a single center, > 15 year outcomes.Surgical endoscopy · 2026Article
- Weight Changes From Glucagon-Like Peptide-1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study.Obesity (Silver Spring, Md.) · 2026Article
- Partnerships With Health Plans to Link Data From Electronic Health Records to Claims for Research Using PCORnet®.Medical care · 2026Article
- Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.JAMA network open · 2026Article
- Topical Volumizing Cream Improves Facial Volume and Skin Health in Adults With Rapid Weight Loss From Pharmacologic (GLP-1/GIP Agonists), Surgical, or Behavioral Interventions.Journal of cosmetic dermatology · 2026Article
- Article
- Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report.The American journal of case reports · 2025Article
- Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics.International journal of obesity (2005) · 2025Article
- The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.International journal of molecular sciences · 2025Review
- Healthcare costs and treatment patterns associated with glucagon-like peptide 1 receptor agonist use among patients with metabolic dysfunction-associated steatohepatitis.Journal of comparative effectiveness research · 2025Article
- Malnutrition is Common in Patients Utilizing Glucagon-Like Peptide-1 Agonists Prior to Total Joint Arthroplasty.Arthroplasty today · 2025Article
- Nanomedicine targeting PPAR in adipose tissue macrophages improves lipid metabolism and obesity-induced metabolic dysfunction.Science advances · 2025Article
- Evaluating Cardio-Protective Molecules by Efficacy Based on Weight Reduction and HbA1c Targets.Biomedicines · 2025Article
- Real-World Sex Differences in Response to Treatment with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Single-Center Outpatient Case Series.Medicina (Kaunas, Lithuania) · 2025Article
- Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery.Nature medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveWeight loss achieved with standard doses of glucagon-like peptide-1 (GLP-1) agonists among real-world patients with type 2 diabetes has not been determined. This study sought to describe the percent change in body weight 72 weeks after starting a GLP-1 agonist.
methodsA retrospective cohort study of nonpregnant adults who were first dispensed a GLP-1 agonist between 2011 and 2018 was conducted using electronic health record data from patients receiving care at a large health system. Linear mixed models were used, with a person-level random intercept controlling for baseline variables associated with missing weight data to estimate percent body weight change during follow-up.
resultsThe cohort included 2405 patients (mean [SD] age 48 [10] years, 53% female), with a mean BMI of 37 (8) kg/m
conclusionsIn this real-world study of more than 2400 patients with overweight or obesity and type 2 diabetes, starting a GLP-1 agonist at standard glycemic control doses was associated with modest weight loss through 72 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.